复发或难治性霍奇金淋巴瘤儿童患者接受维布妥昔单抗的肺毒性
该回顾性研究评估了19例复发或难治性霍奇金淋巴瘤儿童及年轻成人患者中维布妥昔单抗(Bv)相关肺毒性的发生情况,其中7例(36.8%)接受Bv治疗。单因素分析显示Bv暴露患者发生肺毒性的比值比为4.0(95%CI 0.55-29.18,P=0.17),多因素分析结果相似。肺毒性在本队列中较常见,Bv治疗者更常见但未达统计学显著。
要点
- 19例复发或难治性霍奇金淋巴瘤儿童及年轻成人中,7例(36.8%)接受维布妥昔单抗治疗。
- Bv暴露者肺毒性比值比为4.0(95%CI 0.55-29.18,P=0.17),未达统计学显著。
- 肺毒性在本队列中较常见,Bv治疗者更常见但差异无统计学意义。
核心结论
- 肺毒性在本队列中较常见,接受Bv治疗者比未接受Bv治疗者更常见,但差异未达统计学显著。
研究设计与样本
- 回顾性评估19例复发或难治性霍奇金淋巴瘤儿童及年轻成人患者,收集患者特征、基线健康状况、治疗方案(包括Bv、博来霉素、吉西他滨、放疗和卡莫司汀的累积剂量)及肺毒性发生情况。
主要发现
- 19例患者中7例(36.8%)接受Bv治疗。
- 单因素分析中,Bv暴露患者发生肺毒性的比值比为4.0(95%CI 0.55-29.18,P=0.17),未达统计学显著。
- 多因素分析结果与单因素分析相似。
临床怎么用
- 原文结论指出,由于霍奇金淋巴瘤患者接受多种可能致肺毒性的治疗,继续评估Bv相关风险至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brentuximab vedotin (Bv) is becoming increasingly important in the treatment of Hodgkin lymphoma (HL), with improved outcomes and an overall favourable toxicity profile. However, Bv is associated with severe pulmonary toxicity when combined with bleomycin, suggesting that additive toxicity may be an important consideration. Furthermore, little has been published on tolerability in paediatric patients. We retrospectively evaluated the occurrence of pulmonary toxicity of Bv in 19 paediatric and young adult patients with relapsed or refractory HL. Patient characteristics, baseline health status, treatment regimens including cumulative doses of Bv, bleomycin, gemcitabine, radiation and carmustine, and the occurrence of pulmonary toxicity were collected. Seven (36·8%) of the 19 patients were treated with Bv. The odds of pulmonary toxicity were 4·0-fold higher (95% confidence interval 0·55-29·18) in patients exposed to Bv compared to unexposed patients in univariate analysis (P = 0·17). Similar results were found in multivariable analysis. Pulmonary toxicity occurred frequently in our cohort and was more common in patients who received Bv than in patients who did not receive Bv, although this was not statistically significant. Because patients with HL are exposed to a myriad of therapies with potential for pulmonary toxicity, continuing to evaluate the risk associated with Bv is critical.
引用
- Faulk KE, Sopfe JM, Campbell K, et al. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. Br J Haematol. 2018. PMID: 30198571. doi:10.1111/bjh.15586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。